Tazobactum%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin-Tazobactam ## Overview Piperacillin-tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. Tazobactam protects piperacillin from degradation by many bacterial beta-lactamases, thereby extending its spectrum of activity against beta-lactamase-producing bacteria. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin-structure infections * Community-acquired pneumonia * Hospital-acquired pneumonia (including ventilator-associated pneumonia) * Bacterial meningitis (in specific situations, depending on local resistance patterns) * Empirical treatment of febrile neutropenia ## Adult Dosing Standard adult dose is 3.375 grams every 6 hours or 4.5 grams every 6 or 8 hours, administered intravenously (IV). * **3.375 g (3 g piperacillin/0.375 g tazobactam) IV q6h** * **4.5 g (4 g piperacillin/0.5 g tazobactam) IV q6h or q8h** Dosing frequency and duration depend on the type and severity of infection, pathogen susceptibility, and clinical response. For severe infections or those caused by less susceptible organisms, higher doses and/or more frequent administration may be necessary. ## Pediatric Dosing Dosing for pediatric patients varies by age and weight, and is often based on piperacillin component per kilogram. Dosing should be based on ideal body weight for obese patients. Consult specific pediatric guidelines or institutional protocols. * **Neonates and Infants (0-1 month):** Generally, 20-30 mg piperacillin/kg per dose IV every 12 hours. * **Children (1 month to 12 years):** Generally, 90-100 mg piperacillin/kg per dose IV every 6 or 8 hours. Do not exceed the maximum adult dose per administration. ## Dose Adjustments * **Renal Impairment:** * CrCl > 40 mL/min: No adjustment needed. * CrCl 20-40 mL/min: 2.25 g IV q6h or 3.375 g IV q8h. * CrCl < 20 mL/min: 2.25 g IV q8h or 3.375 g IV q12h. * Hemodialysis: 2.25 g IV q8h, with an additional 0.75 g dose after each hemodialysis session. Dose adjustments are typically made for both piperacillin and tazobactam components. ## Contraindications * Hypersensitivity to piperacillin, tazobactam, other penicillins, or any component of the formulation. * History of severe allergic reaction (e.g., anaphylaxis) to beta-lactams. ## Adverse Effects * **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia, fever, injection site reactions. * **Serious:** Clostridioides difficile-associated diarrhea (CDAD), hypersensitivity reactions (including anaphylaxis), seizures (especially with high doses or renal impairment), neutropenia, thrombocytopenia, elevated liver enzymes, interstitial nephritis. ## Key Drug Interactions * **Probenecid:** May decrease renal excretion of piperacillin-tazobactam, increasing serum concentrations and potential toxicity. * **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade. * **Warfarin:** May decrease the effect of warfarin; monitor INR closely. * **Methotrexate:** Piperacillin may decrease methotrexate clearance; monitor methotrexate levels. * **Bacteriostatic agents (e.g., tetracyclines, macrolides):** May potentially antagonize the bactericidal effect of piperacillin. ## Monitoring * Renal function (creatinine, BUN) * Liver function tests (LFTs) * Complete blood count (CBC) with differential and platelet count * Signs and symptoms of infection (clinical response) * Signs and symptoms of hypersensitivity reactions * Electrolytes ## Clinical Pearls * This combination is active against many gram-positive, gram-negative, and anaerobic bacteria, including many beta-lactamase-producing strains. * When preparing IV admixtures, avoid simultaneous administration with solutions containing only amino acids. * The reconstituted solution is stable for a limited time; follow manufacturer's recommendations for storage and use. * Consider local antimicrobial resistance patterns when selecting empiric therapy. * Discontinue therapy if hypersensitivity reaction or CDAD is suspected. *** *Disclaimer: This information is intended for healthcare professionals and should not replace independent clinical judgment. Always consult the official prescribing information and current clinical guidelines for complete and up-to-date drug information.*